Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral ...

The drug’s efficacy “looks to be highly competitive” and potentially better than rival pills from Novo and Lilly, BMO Capital ...

KBRA releases research examining lease structures in the data center industry. This industry continues to expand rapidly amid increasing demand for artificial intelligence (AI) compute capacity, cloud ...

Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.

Report examines three-year costs, confidentiality, and operational differences between outsourced teams and AI ...

Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong ...

The annotation, recruitment, grounding, display, and won gates determine which content AI engines trust and recommend. Here’s how it works.

The bridging protocol's team wants to exchange ACX tokens for equity in a new U.S. C-corp or buy holders out at a 25% premium ...

KBRA releases a recap of its Evolving Data Center Landscape: Insights & Implementation Breakfast, where structured finance and project finance professionals gathered in New York on March 12 to discuss ...

Grist reports that the tech industry is spending millions to rebrand data centers amid community pushback over environmental ...